Enliven Therapeutics, Inc. <ELVN.O>: William Blair initiates coverage with outperform rating
ELVN•Related News
Nasdaq Composite still has room to climb
QQQ•
Scribe Therapeutics Inc <SCTX.O>: Leerink Partners initiates coverage with outperform rating; price target $37
SCTX•
DW Energy says rising US LNG exports lift natural gas demand outlook for investors
UNG•
Yields give way
SPY•
Legacy Housing names co-founder Kenneth Shipley chairman, CEO
LEGH•